Arcutis Biotherapeutics Inc (ARQT) Stock Price, Quote & News

Company Profile

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as...

Industry: Biotechnology

Sector: Healthcare

Phone: 805 418 5006

Website: www.arcutis.com

Address:

3027 Townsgate Road, Suite 300, Westlake Village, United States

JFais Jul. 3 at 1:58 PM

Doing another one of these on Tuesday FYI @stevenvig Last one we discussed $GERN $ARQT $SNDX among others (also importance of combatting FOMO with fewer trades per month, rather timely with $XBI at highs) https://seekingalpha.com/article/4828961?gt=f9ee6019a90fb5fc

0 · Reply

Neutin Jun. 30 at 2:58 PM

$ARQT Manipulation? Is that you? 🤓 Don't worry the price will be back up very soon

0 · Reply

Franciscomaligno Jun. 30 at 2:28 PM

$ARQT ...and MMs hits Again. Really pos, sob , mf, and other thousand of theese is what they deserve!!!

0 · Reply

AlertsAndNews Jun. 29 at 11:32 PM

$ARQT FDA approval here FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2

0 · Reply

TwongStocks Jun. 29 at 11:14 PM

$ARQT FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2 https://www.globenewswire.com/news-release/2026/06/29/3319348/0/en/fda-approves-arcutis-zoryve-roflumilast-cream-0-3-for-the-treatment-of-plaque-psoriasis-in-children-as-young-as-age-2.html

0 · Reply

jcwhitey Jun. 29 at 8:35 PM

$ARQT The FDA is the most inconsistent government organization that I know. How can they approve new drugs early that have never been on the market but forget about this drug? For crying out loud it's already on the market. FFS approve it for another indication.

0 · Reply

ixthus77 Jun. 29 at 7:32 PM

$ARQT Aprroximatley 5K-10K of children aged 2-5 in the U.S. experience plaque psoriasis in a given year. Not enough to move the needle revenue wise.

0 · Reply

Rhody27 Jun. 29 at 4:51 PM

$ARQT approval AH

0 · Reply

Neutin Jun. 29 at 6:27 AM

$ARQT Wake up folks! Today we're getting FDA approval

1 · Reply

JFDI Jun. 28 at 11:22 PM

$ARQT

0 · Reply

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 30, 2026, 9:15 AM EDT - 4 days ago

Arcutis Launches New Virtual Health Platform Supporting Access to Care for Individuals Living with Chronic Inflammatory Skin Diseases, Including Approved ZORYVE® (roflumilast) Indications

2026-06-29T23:30:12.000Z - 4 days ago

FDA approves supplemental NDA to expand indication of Arcutis’ Zoryve cream

Jun 29, 2026, 7:06 PM EDT - 4 days ago

FDA Approves Arcutis' ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2

Jun 9, 2026, 2:00 PM EDT - 25 days ago

Arcutis Biotherapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 5, 2026, 10:30 AM EDT - 4 weeks ago

Arcutis Biotherapeutics Transcript: AGM 2026

Jun 3, 2026, 8:00 AM EDT - 4 weeks ago

New Expert Consensus Provides Age-Specific Guidance for Improving Care for Individuals with Genital Psoriasis Published in the American Journal of Clinical Dermatology

May 26, 2026, 4:00 PM EDT - 5 weeks ago

Arcutis Management to Present at Goldman Sachs 47th Annual Global Healthcare Conference

2026-05-07T19:23:54.000Z - 2 months ago

Arcutis Biotherapeutics price target lowered to $34 from $35 at Morgan Stanley

2026-05-07T01:26:52.000Z - 2 months ago

Arcutis Biotherapeutics reports Q1 EPS (9c), consensus (6c)

2026-05-07T01:25:08.000Z - 2 months ago

Arcutis Biotherapeutics backs FY26 revenue view $480M-$495M, consensus $498.07M

May 6, 2026, 4:30 PM EDT - 2 months ago

Arcutis Biotherapeutics Earnings Call Transcript: Q1 2026

May 6, 2026, 4:30 PM EDT - 2 months ago

Arcutis Biotherapeutics Earnings release: Q1 2026

May 6, 2026, 4:30 PM EDT - 2 months ago

Arcutis Biotherapeutics Quarterly report: Q1 2026

May 6, 2026, 4:30 PM EDT - 2 months ago

Arcutis Biotherapeutics Slides: Q1 2026

May 6, 2026, 4:00 PM EDT - 2 months ago

Arcutis Announces First Quarter 2026 Financial Results and Provides Business Update

2026-04-27T13:03:49.000Z - 2 months ago

Arcutis Biotherapeutics submits Zoryve supplemental new drug application

Apr 27, 2026, 8:00 AM EDT - 2 months ago

Arcutis Submits Supplemental New Drug Application to the FDA for ZORYVE® (roflumilast) Cream 0.05% to Expand Indication for Treatment of Atopic Dermatitis to Infants Down to 3 Months

Apr 22, 2026, 8:00 AM EDT - 2 months ago

Arcutis' ZORYVE® (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis Guidelines

Apr 21, 2026, 8:00 AM EDT - 2 months ago

Arcutis Biotherapeutics Proxy statement: Proxy filing

Apr 21, 2026, 8:00 AM EDT - 2 months ago

Arcutis Biotherapeutics Proxy statement: Proxy filing

Apr 15, 2026, 4:00 PM EDT - 2 months ago

Arcutis to Report First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026

Apr 14, 2026, 11:00 AM EDT - 2 months ago

Arcutis Biotherapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference

Mar 31, 2026, 4:00 PM EDT - 3 months ago

Arcutis Management to Present at the 25th Annual Needham Virtual Healthcare Conference

Mar 31, 2026, 7:00 AM EDT - 3 months ago

Arcutis Biotherapeutics Slides: Corporate presentation

2026-03-29T14:30:41.000Z - 3 months ago

Arcutis Biotherapeutics presents new Phase 2 results on Zoryve cream

Mar 28, 2026, 11:00 AM EDT - 3 months ago

Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting

2026-03-18T12:20:35.000Z - 3 months ago

Arcutis Biotherapeutics to present clinical data on ZORYVE at AAD Meeting

Mar 18, 2026, 8:00 AM EDT - 3 months ago

Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at the 2026 American Academy of Dermatology Annual Meeting

2026-03-10T13:12:08.000Z - 4 months ago

Arcutis Biotherapeutics announces publication on Phase 3 study of Zoryve cream

Mar 10, 2026, 9:00 AM EDT - 4 months ago

Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE® (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2–5 in Pediatric Dermatology

2026-03-05T14:07:52.000Z - 4 months ago

Arcutis announces promotion of Matsuda to EVP, Chief Legal Officer

Mar 5, 2026, 9:00 AM EST - 4 months ago

Arcutis Announces Promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer to Support Next Phase of Growth

2026-03-03T13:17:29.000Z - 4 months ago

Arcutis first participant enrolled in Phase 1a/1b trial of ARQ-234-131

Mar 3, 2026, 8:00 AM EST - 4 months ago

Arcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Volunteers and Adults With Atopic Dermatitis

Mar 2, 2026, 1:50 PM EST - 4 months ago

Arcutis Biotherapeutics Transcript: TD Cowen 46th Annual Health Care Conference

2026-03-02T12:01:36.000Z - 4 months ago

Arcutis Biotherapeutics price target lowered to $35 from $37 at Mizuho

Feb 27, 2026, 4:00 PM EST - 4 months ago

Arcutis Management to Present at TD Cowen's 46th Annual Health Care Conference

2026-02-27T12:37:43.000Z - 4 months ago

Arcutis Biotherapeutics price target raised to $35 from $34 at Guggenheim

2026-02-26T14:41:20.000Z - 4 months ago

Arcutis Biotherapeutics price target raised to $35 from $30 at TD Cowen

2026-02-26T12:21:49.000Z - 4 months ago

Arcutis Biotherapeutics price target raised to $35 from $32 at Morgan Stanley

2026-02-26T11:05:11.000Z - 4 months ago

Arcutis Biotherapeutics price target raised to $34 from $30 at H.C. Wainwright

2026-02-25T21:51:17.000Z - 4 months ago

Arcutis Biotherapeutics files automatic mixed securities shelf

2026-02-25T21:50:28.000Z - 4 months ago

Arcutis Biotherapeutics files to sell common stock for holders, no amount given

Feb 25, 2026, 4:30 PM EST - 4 months ago

Arcutis Biotherapeutics Earnings Call Transcript: Q4 2025

Feb 25, 2026, 4:30 PM EST - 4 months ago

Arcutis Biotherapeutics Annual report: Q4 2025

Feb 25, 2026, 4:30 PM EST - 4 months ago

Arcutis Biotherapeutics Earnings release: Q4 2025

Feb 25, 2026, 4:30 PM EST - 4 months ago

Arcutis Biotherapeutics Slides: Q4 2025

2026-02-25T21:08:30.000Z - 4 months ago

Arcutis Biotherapeutics reports Q4 EPS 13c, consensus 9c

Feb 25, 2026, 4:00 PM EST - 4 months ago

Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

2026-02-24T14:27:28.000Z - 4 months ago

Arcutis announces Max Homa joins ‘Free to Be Me’ campaign

Feb 24, 2026, 9:15 AM EST - 4 months ago

Professional Golfer Max Homa Joins Arcutis' Free to Be Me Campaign, Urging Individuals with Seborrheic Dermatitis to Tee Up a Conversation with Their Healthcare Provider About Long-Term Treatments

Feb 11, 2026, 11:30 AM EST - 5 months ago

Arcutis Biotherapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

2026-02-02T13:06:19.000Z - 5 months ago

Arcutis Biotherapeutics announces results for Phase 2 trial of Zoryve

Feb 2, 2026, 8:00 AM EST - 5 months ago

Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE® (roflumilast) Cream 0.05% in Infants with Mild to Moderate Atopic Dermatitis

Jan 26, 2026, 8:00 AM EST - 5 months ago

Arcutis Biotherapeutics, Inc. Announces Termination of Promotion Agreement with Kowa

Jan 22, 2026, 4:00 PM EST - 5 months ago

Arcutis to Report Fourth Quarter and Full Year 2025 Financial Results and Present at Upcoming Investor Conference

Jan 21, 2026, 8:00 AM EST - 5 months ago

Nationwide Survey Underscores Concerns with Use of Topical Steroids and Need for Long-Term Treatment Strategies Facing the 46 Million Americans with Chronic Inflammatory Skin Conditions

Jan 12, 2026, 8:00 AM EST - 6 months ago

Arcutis Highlights 2026 Strategic Priorities and Anticipated Milestones

Dec 8, 2025, 4:00 PM EST - 7 months ago

Arcutis Strengthens Board of Directors with New Appointment of Amit Munshi and Honors Retirement of Bhaskar Chaudhuri

Nov 17, 2025, 8:00 AM EST - 8 months ago

FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5

Nov 13, 2025, 8:00 AM EST - 8 months ago

Arcutis Completes Enrollment in INTEGUMENT-INFANT Phase 2 Study Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis

Nov 11, 2025, 8:30 AM EST - 8 months ago

Arcutis Biotherapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 4, 2025, 8:00 AM EST - 8 months ago

Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data of ZORYVE® (roflumilast) Foam 0.3% in Individuals with Seborrheic Dermatitis in American Journal of Clinical Dermatology

Oct 30, 2025, 9:15 AM EDT - 8 months ago

Mother-Daughter Duo, Tori Spelling and Stella McDermott, Partner With Arcutis Biotherapeutics in the Free to Be Me Campaign, Urging People With Inflammatory Skin Conditions to Speak With Their Healthcare Provider About Long-Term Treatments

Oct 30, 2025, 8:00 AM EDT - 8 months ago

Arcutis Launches ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Children Ages 2 to 5

Oct 28, 2025, 10:30 AM EDT - 8 months ago

Arcutis Biotherapeutics Transcript: Q3 & Investor Day 2025

Oct 28, 2025, 10:30 AM EDT - 8 months ago

Arcutis Biotherapeutics Earnings release: Q3 2025

Oct 28, 2025, 10:30 AM EDT - 8 months ago

Arcutis Biotherapeutics Quarterly report: Q3 2025

Oct 28, 2025, 10:30 AM EDT - 8 months ago

Arcutis Biotherapeutics Slides: Q3 2025

Oct 28, 2025, 8:30 AM EDT - 8 months ago

Arcutis Outlines Strategy for Driving Sustainable Growth and Announces Third Quarter 2025 Financial Results

Oct 27, 2025, 4:00 PM EDT - 8 months ago

Arcutis to Present at Upcoming Investor Conferences

Oct 24, 2025, 8:00 AM EDT - 9 months ago

Arcutis to Present New Quality of Life and Long-Term Data with ZORYVE® (roflumilast) Cream 0.15% and 0.05% for the Treatment of Atopic Dermatitis at the Fall Clinical Dermatology Conference

Oct 16, 2025, 7:00 AM EDT - 9 months ago

Arcutis Biotherapeutics Slides: Corporate Presentation

Oct 6, 2025, 8:00 AM EDT - 9 months ago

FDA Approves Arcutis' ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5

Sep 29, 2025, 4:00 PM EDT - 9 months ago

Arcutis Biotherapeutics to Host Virtual Investor Day and Report Third Quarter 2025 Financial Results on October 28, 2025

Sep 17, 2025, 4:00 AM EDT - 10 months ago

Arcutis To Present Multiple New ZORYVE® (roflumilast) Data Analyses at European Academy of Dermatology and Venereology Congress

Sep 16, 2025, 9:00 AM EDT - 10 months ago

Allure Magazine Honors Arcutis' ZORYVE® (roflumilast) with Prestigious Best of Beauty Breakthrough Award

Sep 10, 2025, 10:30 AM EDT - 10 months ago

Arcutis Biotherapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 9, 2025, 2:35 PM EDT - 10 months ago

Arcutis Biotherapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 3, 2025, 11:43 AM EDT - 10 months ago

Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% to Expand Indication for Treatment of Plaque Psoriasis in Children Ages 2 to 5

Sep 3, 2025, 9:45 AM EDT - 10 months ago

Arcutis Biotherapeutics Transcript: Citi's Biopharma Back to School Conference

Aug 6, 2025, 4:30 PM EDT - 11 months ago

Arcutis Biotherapeutics Earnings Call Transcript: Q2 2025

Aug 6, 2025, 4:30 PM EDT - 11 months ago

Arcutis Biotherapeutics Quarterly report: Q2 2025

Aug 6, 2025, 4:30 PM EDT - 11 months ago

Arcutis Biotherapeutics Earnings release: Q2 2025

Aug 6, 2025, 4:30 PM EDT - 11 months ago

Arcutis Biotherapeutics Slides: Q2 2025

Aug 6, 2025, 4:00 PM EDT - 11 months ago

Arcutis Announces Second Quarter 2025 Financial Results and Provides Business Update

Jul 23, 2025, 4:00 PM EDT - 1 year ago

Arcutis to Report Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025

Jun 26, 2025, 8:00 AM EDT - 1 year ago

Arcutis' ZORYVE® (roflumilast) Cream 0.15% Receives Strong Recommendation in American Academy of Dermatology Updated Guidelines for Adult Atopic Dermatitis

Jun 10, 2025, 4:00 PM EDT - 1 year ago

Arcutis Biotherapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 10, 2025, 8:00 AM EDT - 1 year ago

Arcutis Enrolls First Child in INTEGUMENT-INFANT Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis

Jun 6, 2025, 8:00 AM EDT - 1 year ago

Arcutis to Present New Long-Term Results of ZORYVE® (roflumilast) Cream at the 2025 Revolutionizing Atopic Dermatitis Conference

May 29, 2025, 4:00 PM EDT - 1 year ago

Arcutis to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

May 22, 2025, 2:12 PM EDT - 1 year ago

Arcutis' ZORYVE® (roflumilast) Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and Older

May 15, 2025, 9:29 AM EDT - 1 year ago

New Consensus Statements on Impact of Genital Psoriasis on Patients from Genital Psoriasis Wellness Consortium Published in Journal of the European Academy of Dermatology and Venereology Clinical Practice

May 7, 2025, 11:18 AM EDT - 1 year ago

Arcutis Announces Publication of Positive Data from ARRECTOR Trial Evaluating ZORYVE® (roflumilast) Foam 0.3% in Individuals with Psoriasis in Journal of American Medical Association Dermatology

May 6, 2025, 4:30 PM EDT - 1 year ago

Arcutis Biotherapeutics Earnings Call Transcript: Q1 2025

May 6, 2025, 4:30 PM EDT - 1 year ago

Arcutis Biotherapeutics Quarterly report: Q1 2025

May 6, 2025, 4:30 PM EDT - 1 year ago

Arcutis Biotherapeutics Earnings release: Q1 2025

May 6, 2025, 4:30 PM EDT - 1 year ago

Arcutis Biotherapeutics Slides: Q1 2025

May 6, 2025, 4:00 PM EDT - 1 year ago

Arcutis Announces First Quarter 2025 Financial Results and Provides Business Update

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Arcutis Biotherapeutics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Arcutis Biotherapeutics Proxy statement: Proxy Filing

Apr 17, 2025, 8:00 AM EDT - 1 year ago

Arcutis to Report First Quarter 2025 Financial Results and Host Conference Call on May 6, 2025

Apr 10, 2025, 4:30 PM EDT - 1 year ago

Arcutis Announces Chief Financial Officer Transition

Apr 8, 2025, 11:00 AM EDT - 1 year ago

Arcutis Biotherapeutics Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 2, 2025, 1:16 PM EDT - 1 year ago

Arcutis and Padagis Agree to Stay Patent Lawsuit

JFais Jul. 3 at 1:58 PM

0 · Reply

Neutin Jun. 30 at 2:58 PM

$ARQT Manipulation? Is that you? 🤓 Don't worry the price will be back up very soon

0 · Reply

Franciscomaligno Jun. 30 at 2:28 PM

$ARQT ...and MMs hits Again. Really pos, sob , mf, and other thousand of theese is what they deserve!!!

0 · Reply

AlertsAndNews Jun. 29 at 11:32 PM

$ARQT FDA approval here FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2

0 · Reply

TwongStocks Jun. 29 at 11:14 PM

0 · Reply

jcwhitey Jun. 29 at 8:35 PM

0 · Reply

ixthus77 Jun. 29 at 7:32 PM

$ARQT Aprroximatley 5K-10K of children aged 2-5 in the U.S. experience plaque psoriasis in a given year. Not enough to move the needle revenue wise.

0 · Reply

Rhody27 Jun. 29 at 4:51 PM

$ARQT approval AH

0 · Reply

Neutin Jun. 29 at 6:27 AM

$ARQT Wake up folks! Today we're getting FDA approval

1 · Reply

JFDI Jun. 28 at 11:22 PM

$ARQT

0 · Reply

Night_Owl_Biotech Jun. 27 at 2:24 PM

@DeadInvestor Attached are formally updated $TVTX multiples versus all other commercial-stage non-oncology bios with pre-12/31/23 approvals. All Others We're a tad surprised to see $ALNY on our trackers, at what appear reasonable multiples versus peers. ALNY specific comments? We also thought $XERS would be more expensive As always, this is not investment advice. $ARQT $XBI

1 · Reply

win0rgohome Jun. 26 at 4:12 AM

@Steve_TheBull_Rogers any suggestions on playing the following $UNCY, $VRDN, $ARQT, $LNTH

2 · Reply

Merlintrader Jun. 25 at 10:31 AM

$LNTH 4 FDA PDUFA Dates — Week of June 29–30, 2026 $ARQT $UNCY $VRDN https://www.merlintrader.com/4-fda-pdufa-dates-week-of-june-29-30-2026/

0 · Reply

Merlintrader Jun. 25 at 8:17 AM

$ARQT Merlintrader Stock Hub • Updated June 25, 2026 Arcutis Biotherapeutics (Nasdaq: $ARQT): ZORYVE Growth, Pediatric PDUFA june 29 , Commercial Execution and the Next Dermatology Catalyst Stack https://www.merlintrader.com/arcutis-biotherapeutics-stock-hub/

0 · Reply

Rhody27 Jun. 24 at 3:48 PM

$ARQT heading to New ATH.

1 · Reply

Dontlookkid Jun. 19 at 10:43 AM

$ARQT next couple down days I’m adding here

0 · Reply

JazzyJ03 Jun. 19 at 7:35 AM

$ARQT long

0 · Reply

Franciscomaligno Jun. 18 at 8:42 PM

$ARQT even in AH !!!

0 · Reply

leonbnu Jun. 18 at 8:06 PM

$ARQT huge volume today🤔

0 · Reply

Neutin Jun. 18 at 4:20 PM

$ARQT It seems like no one knows there's an FDA approval coming on the 29th of this month.🤷‍♂️

0 · Reply

Rhody27 Jun. 17 at 3:08 PM

$ARQT this is a hidden 💎.

1 · Reply

Neutin Jun. 15 at 4:20 PM

$ARQT Let's touch on 30 🥰

0 · Reply

Market Cap	3.23B
Revenue (ttm)	376.07M
Net Income (ttm)	-16.14M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	172.27
Profit Margin	-4.29%
Debt to Equity Ratio	0.58

Volume	1,198,100
Avg Vol	1,873,516
Day's Range	N/A - N/A
Shares Out	125.08M
Stochastic %K	10%
Beta	1.48
Analysts	Strong Sell
Price Target	$34.62